128k views
5 votes
DPP-4 inhibitors slow the breakdown of GLP-1 in the body, prolonging the effects of increased insulin secretion, decreased glucagon secretion, and slowed GI emptying.

Options:
A. True
B. False

1 Answer

4 votes

Final answer:

The statement is true; DPP-4 inhibitors extend the action of GLP-1, increasing insulin secretion, reducing glucagon levels, and slowing gastrointestinal emptying, thereby aiding in blood glucose control.

Step-by-step explanation:

The statement that DPP-4 inhibitors slow the breakdown of GLP-1 in the body, prolonging the effects of increased insulin secretion, decreased glucagon secretion, and slowed GI emptying is true. DPP-4 inhibitors are a class of medications used in the management of type 2 diabetes. They work by blocking the enzyme DPP-4, which normally breaks down incretin hormones such as GLP-1 (glucagon-like peptide-1). GLP-1 is crucial in regulating blood sugar levels by enhancing the secretion of insulin, which decreases blood glucose levels, and inhibiting glucagon, which would otherwise increase blood glucose levels. Additionally, GLP-1 slows gastric emptying, which contributes to satiety and further helps in blood glucose management. Therefore, by inhibiting DPP-4 and enhancing GLP-1's effects, blood sugar control is improved in diabetic patients.

  • DPP-4 inhibitors block the enzyme DPP-4, slowing the breakdown of GLP-1.
  • GLP-1 increases insulin and decreases glucagon secretion.
  • DPP-4 inhibition prolongs insulin secretion, reduces glucagon levels, and slows GI emptying.

User Andrew Slaughter
by
7.6k points
Welcome to QAmmunity.org, where you can ask questions and receive answers from other members of our community.